Search Result

Results for "

PCSK9

" in MedChemExpress (MCE) Product Catalog:

By Targets:	PCSK9 (75) Amyloid-β (1) ANGPTL (1) Apoptosis (1) Autophagy (1) Fatty Acid Synthase (FASN) (1) HSV (1) Interleukin Related (1) LDLR (3) NF-κB (1) Ser/Thr Protease (4) Small Interfering RNA (siRNA) (4) Toll-like Receptor (TLR) (1)
By Research Areas:	Cancer (8) Cardiovascular Disease (39) Infection (1) Inflammation/Immunology (5) Metabolic Disease (39) Neurological Disease (1)
Oligonucleotides:	Pre-designed siRNA Sets (1) Antisense Oligonucleotides (9) siRNAs (7)

Inhibitors & Agonists

Peptides

Inhibitory Antibodies

Natural
Products

Recombinant Proteins

Antibodies

Oligonucleotides

Targets Recommended: PCSK9

Cat. No.	Product Name	Target	Research Areas	Chemical Structure

HY-130245

PCSK9 degrader 1	PCSK9	Metabolic Disease
PCSK9 degrader 1 (Compound 16) is a small molecule ligand for proprotein convertase substilisin-like/kexin type 9 (PCSK9) and shows high affinity to *PCSK9* with a K_i of 107 nM. PCSK9 degrader 1 can involve in a protein-protein interaction with the low-density lipoprotein (LDL) receptor .

HY-128334

PCSK9 modulator-2	PCSK9	Metabolic Disease
PCSK9 modulator-2 (Compound 1) is a potent modulator of *PCSK9* with an EC₅₀ value of 202 nM. PCSK9 is a recently validated target for lowering low-density lipoprotein cholesterol (LDL-C). PCSK9 modulator-2 has the potential for the research of hyperlipidemia .

HY-146084

PCSK9 modulator-3	PCSK9	Metabolic Disease
PCSK9 modulator-3 (Compound 13) is a potent modulator of *PCSK9* with an EC₅₀ value of 2.46 nM. PCSK9 is a recently validated target for lowering low-density lipoprotein cholesterol (LDL-C). PCSK9 modulator-3 has the potential for the research of hyperlipidemia .

HY-146085

PCSK9 modulator-4	PCSK9	Metabolic Disease
PCSK9 modulator-4 (Compound 21) is a potent modulator of *PCSK9* with an EC₅₀ value of 0.15 nM. PCSK9 is a recently validated target for lowering low-density lipoprotein cholesterol (LDL-C). PCSK9 modulator-4 has the potential for the research of hyperlipidemia .

HY-141724

PCSK9 ligand 1	PCSK9	Cancer
PCSK9 ligand 1 is a selective proprotein convertase substilisin-like/kexin type 9 (PCSK9) ligand. PCSK9 ligand 1 does not affect PCSK9 function .

HY-164344

PCSK9 allosteric binder-1	PCSK9	Cardiovascular Disease
PCSK9 allosteric binder-1 (example 70) is a *PCSK9* allosteric binder. PCSK9 allosteric binder-1 can be used in the study of cardiovascular diseases .

HY-RS10177

PCSK9 Human Pre-designed siRNA Set A	Small Interfering RNA (siRNA) PCSK9	Others
PCSK9 Human Pre-designed siRNA Set A contains three designed siRNAs for PCSK9 gene (Human), as well as a negative control, a positive control, and a FAM-labeled negative control.

PCSK9 Human Pre-designed siRNA Set A PCSK9 Human Pre-designed siRNA Set A

HY-163141

PCSK9-IN-24	PCSK9	Cardiovascular Disease
PCSK9-IN-24 (Compound OY3) is a compound that targets *PCSK9. PCSK9-IN-24 reduces PCSK9* levels and increases LDL uptake and may be used in atherosclerosis research .

HY-161434

PCSK9-IN-26	PCSK9	Metabolic Disease
PCSK9-IN-26 (Compound 116) is an *PCSK9* inhibitor (IC₅₀ < 1 nM). PCSK9-IN-26 can be used for metabolic research .

HY-157434

PCSK9-IN-23	PCSK9	Cardiovascular Disease
PCSK9-IN-23 (compound 5C) is a potent *PCSK9* inhibitor. PCSK9-IN-23 blocks PCSK9 secretion from HepG2 cells, significantly increases LDL receptor (LDLR) expression .

HY-153453

PCSK9-IN-17	PCSK9	Cardiovascular Disease
PCSK9-IN-17 is a *PCSK9* inhibitor. PCSK9-IN-17 can be used for the research of cholesterol metabolism (WO2020150474A1, compound 105) .

HY-155415

PCSK9-IN-20	PCSK9	Cardiovascular Disease
PCSK9-IN-20 (Compound 3i) is a *PCSK9* inhibitor with an IC₅₀ of 3.96 µM. PCSK9-IN-20 decreases PCSK9 and increases LDLR protein expression in vitro .

HY-160036

PCSK9-IN-22	PCSK9	Metabolic Disease
PCSK9-IN-22 (compound 29) is an orally active inhibitor of *PCSK9. PCSK9*-IN-22 inhibits the interaction of the protein with LDLR in vivo .

HY-148758

PCSK9-IN-13	PCSK9	Metabolic Disease
PCSK9-IN-13(compound 3f) is a potent *PCSK9* inhibitor, which can antagonize low-density lipoprotein (LDL) receptor binding by binding to PCSK9, with an IC₅₀ of 537 nM .

HY-148673

AZD0780 PCSK9-IN-12	PCSK9	Metabolic Disease
PCSK9-IN-12 is a heteroaryl compound. PCSK9-IN-12 has bind affinity for *PCSK9* with a K_d value of ＜200 nM. PCSK9-IN-12 can be used for the research of cholesterol metabolism .

HY-159595

PCSK9-IN-29	LDLR PCSK9	Metabolic Disease Inflammation/Immunology
PCSK9-IN-29 is a lipid-lowering agent. PCSK9-IN-29 can increase low-density lipoprotein receptor (LDLR) protein expression and decrease *PCSK9* protein expression in hepG2 cells. PCSK9-IN-29 can reduce the levels of serum LDL-C, TC, and liver enzyme ALT in crab eating macaques fed a high-fat diet, lower body weight and fat, and increase bone mineral content. PCSK9-IN-29 can be used for research on non-alcoholic fatty liver disease and obesity .

HY-152221

PCSK9-IN-10	PCSK9	Metabolic Disease
PCSK9-IN-10 is a potent and orally active *PCSK9* inhibitor with an IC₅₀ value of 6.4 µM. PCSK9-IN-10 increases the expression of LDLR protein and decreases the expression of PCSK9. PCSK9-IN-10 reduces atherosclerosis progression. PCSK9-IN-10 has the potential for the research of hyperlipidemia .

HY-152223

PCSK9-IN-11	PCSK9	Cardiovascular Disease
PCSK9-IN-11 (compound 5r) is a potent and orally active *PCSK9* inhibitor. PCSK9-IN-11 exhibits PCSK9 transcriptional inhibitory activity in HepG2 cells, with an IC₅₀ of 5.7 μM. PCSK9-IN-11 increases LDL receptor (LDLR) protein level. PCSK9-IN-11 can be used for atherosclerosis research .

HY-N10702

PCSK9-IN-9	PCSK9	Cardiovascular Disease
PCSK9-IN-9 is an isocoumarins of natural origin. PCSK9-IN-9 can inhibit proprotein convertase subtilisin-kexin type 9 (PCSK9), IDOL, and SREBP2 mRNA expression. PCSK9-IN-9 inhibits *PCSK9* with an IC₅₀ value of 11.9 μM .

HY-161940

PCSK9-IN-30	PCSK9	Cardiovascular Disease
PCSK9-IN-30 (Compound 3f) is a *PCSK9* inhibitor. PCSK9-IN-30 interacts with a cryptic binding groove of *PCSK9, inhibiting the binding of PCSK9* to the low-density lipoprotein receptor (LDLR) (IC₅₀ = 537 nM), restoring the uptake of low-density lipoprotein (LDL) by liver cells, and ultimately reducing plasma cholesterol levels. PCSK9-IN-30 exhibits good bioavailability in mice and can be used for research in the field of cardiovascular diseases .

HY-161435

PCSK9-IN-27	PCSK9	Metabolic Disease
PCSK9-IN-27 (Compound 108) is a *PCSK9* inhibitor (IC₅₀: 3.4 nM). PCSK9-IN-27 reduces LDLR degradation and increases LDL-C uptake .

HY-155006

PCSK9-IN-19	PCSK9	Metabolic Disease
PCSK9-IN-19 (Compound 1) is a *PCSK9* inhibitor. PCSK9-IN-19 can be used for research of high LDL-cholesterol levels and prevention of coronary artery disease .

HY-153452

PCSK9-IN-16	PCSK9	Cardiovascular Disease
PCSK9-IN-16 is a potent *PCSK9* inhibitor. PCSK9-IN-16 is extracted from patent WO2020150474, example 87, has the potential for hypercholesterolemia and other cardiovascular diseases research .

HY-153454

PCSK9-IN-18	PCSK9	Metabolic Disease
PCSK9-IN-18 (compound 188) is a potent *PCSK9* inhibitor with a K_D value of <200 nM .

HY-153391

PCSK9-IN-14	PCSK9	Metabolic Disease
PCSK9-IN-14 (compound Ia-8) is a potent *PCSK9* inhibitor .

HY-153451

PCSK9-IN-15	PCSK9	Metabolic Disease
PCSK9-IN-15 (compound 5) is a potent inhibitor of proprotein convertase subtilisin/kexin 9 (PCSK9, K_D <200 nM). PCSK9 is involved in cholesterol metabolism and regulates levels of low-density lipoprotein cholesterol (LDL-C) in the blood. PCSK9- in -15 can be used to study cholesterol-lowering and dyslipidemia .

HY-134482

PCSK9-IN-1	PCSK9	Cardiovascular Disease
PCSK9-IN-1 is a novel and highly potent cyclic peptide *PCSK9* inhibitor with a K_i value of 1.46 nM.

HY-N13083

PCSK9-IN-28	PCSK9	Cardiovascular Disease
PCSK9-IN-28 (Compound C11) is a *PCSK9* inhibitor that can be isolated from Euphorbia esula. By binding to HNF1α, PCSK9-IN-28 inhibits PCSK9 transcription by binding to HNF1α and affecting its nuclear distribution, thereby enhancing LDLR and promoting LDL uptake. PCSK9-IN-28 exhibits significant lipid-lowering activity in the high-fat diet (HFD) mouse model and can be used in the study of hyperlipidemia .

HY-139998

PCSK9-IN-3	PCSK9	Cardiovascular Disease
PCSK9-IN-3 is a novel, highly potent, and orally bioavailable next-generation tricyclic peptide *PCSK9* inhibitor.

HY-168156

PCSK9-IN-32	PCSK9	Cancer
PCSK9-IN-32 (compund 8) is a *PCSK9*[1:33]-GFP translation inhibitor .

HY-161942

PCSK9-IN-31	PCSK9	Metabolic Disease
PCSK9-IN-31 (Compound WX002) is an orally active *PCSK9* inhibitor. PCSK9-IN-31 can lower low-density lipoprotein cholesterol (LDL-C) and total cholesterol (TC) in high cholesterol fed model rats .

HY-132897

PCSK9-IN-2	PCSK9	Cardiovascular Disease
PCSK9-IN-2 is a novel small molecule inhibitor of *PCSK9-LDLR* protein–protein interaction (PPI) with an IC₅₀ value of 7.57 μM.

HY-P9928A

*Alirocumab (anti-PCSK9)* 1 Publications Verification REGN 727(anti-PCSK9); SAR 236553(anti-PCSK9)	PCSK9	Cardiovascular Disease
Alirocumab (anti-PCSK9) is a human monoclonal antibody inhibiting proprotein convertase subtilisin/kexin type 9 *(PCSK9). Alirocumab specifically binds PCSK9*, a down regulator of liver low-density lipoprotein (LDL)-receptors, thereby increasing the ability of the liver to bind LDL-cholesterol (LDL-C) and reducing levels of LDL-C in blood. Alirocumab can be used for the research of hypercholesterolemia .

HY-130245A

*(R,R)-PCSK9* degrader 1**	PCSK9	Metabolic Disease
(R,R)-PCSK9 degrader 1 is the isomer of PCSK9 degrader 1 (HY-130245). PCSK9 degrader 1 (Compound 16) is a small molecule ligand for proprotein convertase substilisin-like/kexin type 9 (PCSK9) and shows high affinity to *PCSK9* with a K_i of 107 nM. PCSK9 degrader 1 can involve in a protein-protein interaction with the low-density lipoprotein (LDL) receptor .

HY-147252

Bezeparsen	PCSK9	Metabolic Disease
Bezeparsen is a PCSK9 synthesis inhibitor .

HY-147252A

Bezeparsen sodium	PCSK9	Metabolic Disease
Bezeparsen sodium is a PCSK9 synthesis inhibitor .

HY-P99626

Frovocimab LY 3015014	PCSK9	Metabolic Disease
Frovocimab (LY 3015014) is a humanized IgG4 monoclonal antibody (mAb) that neutralizes *PCSK9. Frovocimab inhibits PCSK9* binding to LDL receptor (LDLR) while permitting the normal proteolytic cleavage of the bound intact PCSK9 .

HY-162562

E28362	PCSK9	Cardiovascular Disease
E28362 is a novel small molecule *PCSK9* inhibitor. E28362 blocks the interaction between *PCSK9* and LDLR, thereby preventing the degradation of LDLR and maintaining cholesterol homeostasia. E28362 is a promising lead compound for the study of hyperlipidemia and atherosclerosis .

HY-P99822

Recaticimab SHR-1209	PCSK9	Metabolic Disease
Recaticimab (SHR-1209) is a humanized monoclonal antibody that inhibits *PCSK9. Recaticimab can bind to PCSK9* and mediate its degradation, increasing the level of low-density lipoprotein (LDL) receptors on the surface of liver cells, reducing the level of LDL in plasma, thereby lowering blood lipids. Recaticimab can be used for the study of hypercholesterolemia .

HY-149310

Dim16	Ser/Thr Protease	Metabolic Disease
Dim16 is a dual *PCSK9/HMG-CoAR* inhibitor, with an IC₅₀ value of 19 nM for PCSK9. Dim16 inhibits PCSK9-LDLR binding with an IC₅₀ value of 0.8 nM. Dim16 increases LDL uptake in HepG2 cells .

HY-161941

MeIm	LDLR PCSK9	Cardiovascular Disease
MeIm (compound 7) is a high-affinity *PCSK9* targeting peptide mimetic with cholesterol-lowering activity. MeIm increases cellular uptake of LDL (EC₅₀=6.04 μM) by inhibiting the binding of *PCSK9* to LDLR (IC₅₀=11.2 μM). MeIm can be used in the study of cardiovascular diseases .

HY-P99696

Lerodalcibep LIB003	PCSK9	Cardiovascular Disease Metabolic Disease
Lerodalcibep (LIB003) is a recombinant fusion protein of a PCSK9-binding domain (adnectin) and human serum albumin. Lerodalcibep is a Lipid-lowering agent. Lerodalcibep can be used for the research of hypercholesterolemia and cardiovascular diseases .

HY-163794

DC371739	ANGPTL PCSK9	Metabolic Disease
DC371739 is a potent and orally activity *PCSK9* inhibitor. DC371739 decreases the mRNA expression of PCSK9 and ANGPTL3. DC371739 decreases the protein expression of PCSK9 and increases the protein expression of LDLR. DC371739 has the potential for the research of hyperlipidemia .

HY-148689

SPC4061	PCSK9	Metabolic Disease
SPC4061 an antisense nucleotide, is a potent *PCSK9* inhibitor. SPC4061 targets the lock-in nucleic acid (LNA) of PCSK9 for the study of hypercholesterolemia and related diseases .

HY-148689A

SPC4061 sodium	PCSK9	Metabolic Disease
SPC4061 an antisense nucleotide, sodium is a potent *PCSK9* inhibitor. SPC4061 targets the lock-in nucleic acid (LNA) of PCSK9 for the study of hypercholesterolemia and related diseases .

HY-12402

SBC-115076 1 Publications Verification	PCSK9	Cardiovascular Disease
SBC-115076 is a potent proprotein convertase subtilisin/kexin type 9 (PCSK9) inhibitor. PCSK9 is a proprotein convertase, which plays a crucial role in LDL receptor metabolism .

HY-101354

R-IMPP PF-00932239	PCSK9	Cardiovascular Disease Cancer
R-IMPP (PF-00932239) is an anti-secretagogue of *PCSK9* (IC₅₀=4.8 μM), which targets the 80S ribosome to inhibit PCSK9 protein translation .

HY-W510159

5-O-Methylembelin	PCSK9	Cardiovascular Disease
5-O-Methylembelin is a natural isocoumarin that inhibits *PCSK9, inducible degrader of the low-density lipoprotein receptor (IDLR), and sterol regulatory element binding protein 2 (SREBP2)* mRNA expression .

HY-P9930

Evolocumab 2 Publications Verification AMG 145	NF-κB Ser/Thr Protease Toll-like Receptor (TLR)	Cardiovascular Disease Metabolic Disease Inflammation/Immunology Cancer
Evolocumab (AMG 145) is a human monoclonal antibody that inhibits *PCSK9. Evolocumab is used in the study of hypercholesterolemia and atherosclerotic cardiovascular disease. Evolocumab binds to circulating PCSK9* protein and inhibits its binding to LDLR. Evolocumab has antioxidant and cytoprotective activities against H₂O₂-induced oxidative damage to endothelial cells. Evolocumab may also negatively regulate activation of the TLR-4/NF-κB signaling pathway to prevent inflammation .

HY-120088A

PF-06446846 hydrochloride 3 Publications Verification	PCSK9	Cardiovascular Disease
PF-06446846 hydrochloride is an orally active and highly selective inhibitor of translation of Proprotein convertase subtilisin/kexin type 9 (PCSK9). PF-06446846 hydrochloride inhibits PCSK9 by inducing the ribosome to stall around codon 34 .

Cat. No.	Product Name	Target	Research Area

HY-P2276

Pep2-8	PCSK9	Cancer
Pep2-8 is a *PCSK9* inhibitor with a binding K_D of 0.7 μM and an IC₅₀ of 1.4 μM .

HY-P2276A

Pep2-8 TFA	PCSK9	Cardiovascular Disease Others
Pep2-8 is a peptide which has enhanced the antagonistic activity of proprotein convertase subtilin/ kexin 9 type (PCSK9) .

HY-P4153

Enlicitide chloride MK-0616 chloride	Ser/Thr Protease	Cardiovascular Disease
Enlicitide chloride is a potent PCSK9 antagonist. Enlicitide chloride can be used in the study of cardiovascular diseases such as atherosclerosis, hypercholesterolemia, coronary heart disease, metabolic syndrome, acute coronary syndrome or related cardiovascular and cardiometabolic disorders[1] .

Cat. No.	Product Name	Target	Research Area

HY-P9928A

*Alirocumab (anti-PCSK9)* 1 Publications Verification REGN 727(anti-PCSK9); SAR 236553(anti-PCSK9)	PCSK9	Cardiovascular Disease
Alirocumab (anti-PCSK9) is a human monoclonal antibody inhibiting proprotein convertase subtilisin/kexin type 9 *(PCSK9). Alirocumab specifically binds PCSK9*, a down regulator of liver low-density lipoprotein (LDL)-receptors, thereby increasing the ability of the liver to bind LDL-cholesterol (LDL-C) and reducing levels of LDL-C in blood. Alirocumab can be used for the research of hypercholesterolemia .

HY-P99822

Recaticimab SHR-1209	PCSK9	Metabolic Disease
Recaticimab (SHR-1209) is a humanized monoclonal antibody that inhibits *PCSK9. Recaticimab can bind to PCSK9* and mediate its degradation, increasing the level of low-density lipoprotein (LDL) receptors on the surface of liver cells, reducing the level of LDL in plasma, thereby lowering blood lipids. Recaticimab can be used for the study of hypercholesterolemia .

HY-P9930

Evolocumab 2 Publications Verification AMG 145	NF-κB Ser/Thr Protease Toll-like Receptor (TLR)	Cardiovascular Disease Metabolic Disease Inflammation/Immunology Cancer
Evolocumab (AMG 145) is a human monoclonal antibody that inhibits *PCSK9. Evolocumab is used in the study of hypercholesterolemia and atherosclerotic cardiovascular disease. Evolocumab binds to circulating PCSK9* protein and inhibits its binding to LDLR. Evolocumab has antioxidant and cytoprotective activities against H₂O₂-induced oxidative damage to endothelial cells. Evolocumab may also negatively regulate activation of the TLR-4/NF-κB signaling pathway to prevent inflammation .

HY-P9928

Alirocumab 1 Publications Verification REGN 727; SAR 236553	PCSK9	Cardiovascular Disease Cancer
Alirocumab (REGN 727) is a human monoclonal antibody inhibitor of *PCSK9*. Alirocumab is a monoclonal antibody. Alirocumab has anti-inflammatory, antiangiogenic and antioxidant effects. Alirocumab can be used in the study of hypercholesterolemia .

HY-P99552

Tafolecimab IBI-306	PCSK9	Cardiovascular Disease
Tafolecimab (IBI-306) is a human lgG2 monoclonal antibody that specifically binds *PCSK-9* and reduces LDL-C levels by inhibiting PCSK-9-mediated endocytosis of the LDL receptor, which in turn enhances clearance of LDL-C and leads to a reduction in LDL-C levels. Tafolecimab may be used in studies of hypercholesterolaemia .

HY-P99187

Bococizumab PF-04950615; RN316	PCSK9	Cardiovascular Disease Metabolic Disease
Bococizumab (PF-04950615) is an anti-human PCSK9 inhibitory antibody that reduces LDL cholesterol levels. Bococizumab can be used in the research of hypercholesterolemia .

HY-P99626

Frovocimab LY 3015014	PCSK9	Metabolic Disease
Frovocimab (LY 3015014) is a humanized IgG4 monoclonal antibody (mAb) that neutralizes *PCSK9. Frovocimab inhibits PCSK9* binding to LDL receptor (LDLR) while permitting the normal proteolytic cleavage of the bound intact PCSK9 .

HY-P99696

Lerodalcibep LIB003	PCSK9	Cardiovascular Disease Metabolic Disease
Lerodalcibep (LIB003) is a recombinant fusion protein of a PCSK9-binding domain (adnectin) and human serum albumin. Lerodalcibep is a Lipid-lowering agent. Lerodalcibep can be used for the research of hypercholesterolemia and cardiovascular diseases .

HY-P99816

Ralpancizumab	PCSK9	Metabolic Disease
Ralpancizumab is a selective *PCSK9* inhibitor with potential application in hemorrhagic stroke .

HY-P99773

Ongericimab JS002	PCSK9	Cardiovascular Disease Metabolic Disease
Ongericimab (JS002) is a humanized anti-PCSK9 monoclonal antibody. Ongericimab has lipid-lowering efficacy. Ongericimab can be used in research of hypercholesteremia and hyperlipidemia .

HY-P99871

Ebronucimab AK102	PCSK9	Others
Ebronucimab (AK102) is an IgG1-λ2 antibody targeting PCSK9 and is primarily expressed by CHO DG44 (Chinese Hamster Ovary) cells .

HY-P990485

*Anti-PCSK9* Antibody**	Inhibitory Antibodies	Inflammation/Immunology

HY-P990658

RG-7652	Inhibitory Antibodies	Inflammation/Immunology

Species:	Human (7) Rhesus Macaque (1) Rat (1) Mouse (2) Cynomolgus (1)
Tag:	His (10) Avi (3) HA (1) Fc (1)
Source:	HEK293 (12)

Cat. No.	Compare	Product Name	Species	Source

HY-P73340

	PCSK9 Protein, Rat (HEK293, His) 1 Publications Verification Proprotein convertase subtilisin/kexin type 9; NARC-1; PC9; PCSK9	Rat	HEK293
	The PCSK9 protein regulates cholesterol levels by interacting with LDLR, VLDLR, LRP1/APOER, and LRP8/APOER2. It promotes their degradation and inhibits their recycling, leading to enhanced LDLR degradation. PCSK9 also affects APOB degradation, BACE1 intermediates, ENaC surface expression, and neuronal apoptosis via LRP8/APOER2. PCSK9 Protein, Rat (HEK293, His) is the recombinant rat-derived PCSK9 protein, expressed by HEK293 , with C-6*His labeled tag.

HY-P73728

	PCSK9 Protein, Human (HEK293, Fc) 1 Publications Verification Proprotein convertase subtilisin/kexin type 9; NARC-1; PC9; PCSK9	Human	HEK293
	The PCSK9 protein is an important regulator of plasma cholesterol homeostasis, affecting LDL receptor family members such as LDLR and VLDLR. It promotes their intracellular degradation and enhances hepatic LDLR degradation through non-proteolytic mechanisms. PCSK9 Protein, Human (HEK293, Fc) is the recombinant human-derived PCSK9 protein, expressed by HEK293 , with C-mFc labeled tag. The total length of PCSK9 Protein, Human (HEK293, Fc) is 662 a.a., with molecular weight of ~97.4 kDa.

HY-P75958

	PCSK9 Protein, Rhesus Macaque (HEK293, His) Proprotein convertase subtilisin/kexin type 9; NARC-1; PC9; PCSK9	Rhesus Macaque	HEK293
	PCSK9 protein regulates cholesterol levels by degrading LDLR, VLDLR, LRP1/APOER and LRP8/APOER2 receptors. It promotes LDLR degradation through non-proteolytic mechanisms, disrupts LDLR recycling, induces LDLR ubiquitination, and inhibits APOB degradation. PCSK9 Protein, Rhesus Macaque (HEK293, His) is the recombinant Rhesus Macaque-derived PCSK9 protein, expressed by HEK293 , with C-His labeled tag. The total length of PCSK9 Protein, Rhesus Macaque (HEK293, His) is 662 a.a., with molecular weight of ~20 & 62 kDa, respectively.

HY-P70966

	PCSK9 Protein, Macaca nemestrina (HEK293, His) Proprotein Convertase Subtilisin/Kexin Type 9; Proprotein Convertase 9; PC9; Subtilisin/Kexin-Like Protease PC9; PCSK9	Cynomolgus	HEK293
	The PCSK9 protein controls plasma cholesterol levels by interacting with LDLR, VLDLR, LRP1/APOER, and LRP8/APOER2 to promote their degradation. It prevents LDLR recycling and directs it to lysosomes for degradation. PCSK9 induces LDLR ubiquitination, inhibits APOB degradation, disposes of BACE1 intermediates, reduces ENaC surface expression, and regulates neuronal apoptosis through LRP8/APOER2. PCSK9 Protein, Macaca nemestrina (HEK293, His) is a recombinant protein dimer complex containing cynomolgus-derived PCSK9 protein, expressed by HEK293 , with C-6*His labeled tag. PCSK9 Protein, Macaca nemestrina (HEK293, His), has molecular weight of (16-21) & (55-77) kDa, respectively.

HY-P78663

	PCSK9 Protein, Human (D374Y, HEK293, His) PCSK9; FH3; HCHOLA3; LDLCQ1; NARC1; PC9	Human	HEK293
	PCSK9 protein, a crucial regulator of plasma cholesterol homeostasis, influences LDL receptor family members like LDLR and VLDLR. It facilitates their degradation within intracellular compartments, enhancing hepatic LDLR degradation through a non-proteolytic mechanism. PCSK9 also exhibits LDLR-independent inhibition of APOB degradation and regulates ENaC-mediated Na(+) absorption, influencing neuronal apoptosis. Notably, it modulates LRP8/APOER2 levels and associated anti-apoptotic pathways. PCSK9 Protein, Human (D374Y, HEK293, His) is the recombinant human-derived PCSK9 protein, expressed by HEK293 , with C-10*His labeled tag and D374Y mutation. The total length of PCSK9 Protein, Human (D374Y, HEK293, His) is 662 a.a., with molecular weight of ~17 & 70 kDa, respectively.

HY-P78824

	PCSK9 Protein, Human (Biotinylated, HEK293, D374Y, His-Avi) PCSK9; FH3; HCHOLA3; LDLCQ1; NARC1; PC9	Human	HEK293
	The PCSK9 protein is an important regulator of plasma cholesterol homeostasis, affecting LDL receptor family members such as LDLR and VLDLR. It promotes their intracellular degradation and enhances hepatic LDLR degradation through non-proteolytic mechanisms. PCSK9 Protein, Human (Biotinylated, HEK293, D374Y, His-Avi) is the recombinant human-derived PCSK9 protein, expressed by HEK293 , with C-Avi, C-His labeled tag and D374Y, , , , mutation.

HY-P71189

	PCSK9 Protein, Mouse (HEK293, His, solution) Proprotein Convertase Subtilisin/Kexin Type 9; Neural Apoptosis-Regulated Convertase 1; NARC-1; Proprotein Convertase 9; PC9; Subtilisin/Kexin-Like Protease PC9; PCSK9; Narc1	Mouse	HEK293
	The PCSK9 protein regulates cholesterol levels by degrading LDLR, VLDLR, LRP1/APOER, and LRP8/APOER2 receptors. It promotes LDLR degradation, inhibits recycling, induces ubiquitination, and affects APOB degradation. Additionally, PCSK9 influences BACE1 intermediates, ENaC surface expression, and neuronal apoptosis by modulating LRP8/APOER2 levels and anti-apoptotic signaling pathways. PCSK9 Protein, Mouse (HEK293, His, solution) is a recombinant protein dimer complex containing mouse-derived PCSK9 protein, expressed by HEK293 , with C-6*His labeled tag. PCSK9 Protein, Mouse (HEK293, His, solution), has molecular weight of 17-19 & 60-66 kDa, respectively.

HY-P70545

	PCSK9 Protein, Human (HEK293, V474I, G670E, His) Proprotein Convertase Subtilisin/Kexin Type 9; Neural Apoptosis-Regulated Convertase 1; NARC-1; Proprotein Convertase 9; PC9; Subtilisin/Kexin-Like Protease PC9; PCSK9; NARC1	Human	HEK293
	The PCSK9 protein is an important regulator of plasma cholesterol homeostasis, affecting LDL receptor family members such as LDLR and VLDLR. It promotes their intracellular degradation and enhances hepatic LDLR degradation through non-proteolytic mechanisms. PCSK9 Protein, Human (HEK293, V474I, G670E, His) is the recombinant human-derived PCSK9 protein, expressed by HEK293 , with C-6*His labeled tag and V474I, G670E, , , mutation. The total length of PCSK9 Protein, Human (HEK293, V474I, G670E, His) is 662 a.a., with molecular weight of 19 & 60 kDa, respectively.

HY-P71189A

	PCSK9 Protein, Mouse (HEK293, His) Proprotein Convertase Subtilisin/Kexin Type 9; Neural Apoptosis-Regulated Convertase 1; NARC-1; Proprotein Convertase 9; PC9; Subtilisin/Kexin-Like Protease PC9; PCSK9; Narc1	Mouse	HEK293
	The PCSK9 protein regulates cholesterol levels by degrading LDLR, VLDLR, LRP1/APOER, and LRP8/APOER2 receptors. It promotes LDLR degradation, inhibits recycling, induces ubiquitination, and affects APOB degradation. Additionally, PCSK9 influences BACE1 intermediates, ENaC surface expression, and neuronal apoptosis by modulating LRP8/APOER2 levels and anti-apoptotic signaling pathways. PCSK9 Protein, Mouse (HEK293, His) is a recombinant protein dimer complex containing mouse-derived PCSK9 protein, expressed by HEK293 , with C-6*His labeled tag. PCSK9 Protein, Mouse (HEK293, His), has molecular weight of 19.37 & 55 kDa, respectively.

HY-P70546

	PCSK9 Protein, Human (Biotinylated, V474I, G670E, HEK293, His-HA-Avi) Proprotein Convertase Subtilisin/Kexin Type 9; Neural Apoptosis-Regulated Convertase 1; NARC-1; Proprotein Convertase 9; PC9; Subtilisin/Kexin-Like Protease PC9; PCSK9; NARC1	Human	HEK293
	The PCSK9 protein is an important regulator of plasma cholesterol homeostasis, affecting LDL receptor family members such as LDLR and VLDLR. It promotes their intracellular degradation and enhances hepatic LDLR degradation through non-proteolytic mechanisms. PCSK9 Protein, Human (Biotinylated, V474I, G670E, HEK293, His-HA-Avi) is the recombinant human-derived PCSK9 protein, expressed by HEK293 , with C-Avi, C-HA, C-8*His labeled tag and V474I, G670E mutation.

HY-P72405

	PCSK9 Protein, Human (Biotinylated, V474I, G670E, HEK293, Avi) Neural Apoptosis-Regulated Convertase 1; NARC-1; Proprotein Convertase 9; PC9	Human	HEK293
	PCSK9 protein, a crucial regulator of plasma cholesterol homeostasis, influences LDL receptor family members like LDLR and VLDLR. It facilitates their degradation within intracellular compartments, enhancing hepatic LDLR degradation through a non-proteolytic mechanism. PCSK9 also exhibits LDLR-independent inhibition of APOB degradation and regulates ENaC-mediated Na(+) absorption, influencing neuronal apoptosis. Notably, it modulates LRP8/APOER2 levels and associated anti-apoptotic pathways. PCSK9 Protein, Human (Biotinylated, V474I, G670E, HEK293, Avi) is the recombinant human-derived PCSK9 protein, expressed by HEK293 , with C-Avi labeled tag and V474I, G670E mutation. The total length of PCSK9 Protein, Human (Biotinylated, V474I, G670E, HEK293, Avi) is 662 a.a., with molecular weight of 19 & 65 kDa, respectively.

HY-P70545A

	PCSK9 Protein, Human (HEK293, C-His) 1 Publications Verification Proprotein Convertase Subtilisin/Kexin Type 9; Neural Apoptosis-Regulated Convertase 1; NARC-1; Proprotein Convertase 9; PC9; Subtilisin/Kexin-Like Protease PC9; PCSK9; NARC1	Human	HEK293
	The PCSK9 protein is an important regulator of plasma cholesterol homeostasis, affecting LDL receptor family members such as LDLR and VLDLR. It promotes their intracellular degradation and enhances hepatic LDLR degradation through non-proteolytic mechanisms. PCSK9 Protein, Human (HEK293, C-His) is the recombinant human-derived PCSK9 protein, expressed by HEK293 , with C-6*His labeled tag. The total length of PCSK9 Protein, Human (HEK293, C-His) is 662 a.a., with molecular weight of approximately 20.33 & 59 kDa, respectively.

Compare Products


Products	In-stock - + Add to Cart
Cat. No.
Species
Source
Tag
Accession
Gene ID
Molecular Weight
Purity
Endotoxin Level
Biological Activity
Appearance
Formulation
Storage & Stability
Shipping
Free Sample	Yes No
Size	* This product has been "discontinued". Optimized version of product available: / In-stock - + Add to Cart Get quote

Cat. No.	Compare	Product Name	Application	Reactivity

HY-P81805

	PCSK9 Antibody (YA1550) HCHOLA3; LDLCQ1; NARC1; Neural apoptosis regulated convertase 1; PC9; PCSK9; Proprotein convertase 9	WB, IP	Human
	PCSK9 Antibody (YA1550) is a rabbit-derived non-conjugated IgG antibody (Clone NO.: YA1550), targeting PCSK9, with a predicted molecular weight of 74 kDa (observed band size: 65/80 kDa). PCSK9 Antibody (YA1550) can be used for WB, IP experiment in human background.

Compare Products


Products	In-stock - + Add to Cart
Cat. No.
Host
Reactivity
Application
Dilution Ratio
Molecular Weight
Conjugation
Clonality
Immunogen
Appearance
Isotype
Gene ID
SwissProt ID
Purity
Formulation
Free Sample	Yes No
Size	* This product has been "discontinued". Optimized version of product available: / In-stock - + Add to Cart Get quote

Cat. No.	Product Name		Classification

HY-143219

SS-Inclisiran sodium		siRNAs
SS-Inclisiran (sodium) is a sense strand of Inclisiran. Inclisiran is a double-stranded small interfering RNA (siRNA) molecule that inhibits the transcription of *PCSK-9* .

HY-143220

SS(no Galnac)-Inclisiran sodium		siRNAs
SS(no Galnac)-Inclisiran (sodium) is a single stran Inclisiran with no GalNAc. Inclisiran is a double-stranded small interfering RNA (siRNA) molecule that inhibits the transcription of *PCSK-9* .

HY-RS10177

PCSK9 Human Pre-designed siRNA Set A		siRNAs Pre-designed siRNA Sets
PCSK9 Human Pre-designed siRNA Set A contains three designed siRNAs for PCSK9 gene (Human), as well as a negative control, a positive control, and a FAM-labeled negative control.

HY-147252

Bezeparsen		Antisense Oligonucleotides
Bezeparsen is a PCSK9 synthesis inhibitor .

HY-147252A

Bezeparsen sodium		Antisense Oligonucleotides
Bezeparsen sodium is a PCSK9 synthesis inhibitor .

HY-148689

SPC4061		Antisense Oligonucleotides
SPC4061 an antisense nucleotide, is a potent *PCSK9* inhibitor. SPC4061 targets the lock-in nucleic acid (LNA) of PCSK9 for the study of hypercholesterolemia and related diseases .

HY-148689A

SPC4061 sodium		Antisense Oligonucleotides
SPC4061 an antisense nucleotide, sodium is a potent *PCSK9* inhibitor. SPC4061 targets the lock-in nucleic acid (LNA) of PCSK9 for the study of hypercholesterolemia and related diseases .

HY-158827A

AZD8233 sodium		Antisense Oligonucleotides
AZD8233 sodium, a liver-targeting antisense oligonucleotide (ASO), inhibits subtilisin/kexin type 9 (PCSK9) protein synthesis. AZD8233 sodium increases the available LDL receptors by reducing PCSK9 levels, thereby clearing LDL from the blood and decreasing LDL-C levels.

HY-158827

AZD8233		Antisense Oligonucleotides
AZD8233, a liver-targeting antisense oligonucleotide (ASO), inhibits proprotein convertase subtilisin/kexin type 9 (PCSK9) protein synthesis. AZD8233 increases the available LDL receptors by reducing PCSK9 levels, thereby clearing LDL from the blood and decreasing LDL-C levels.

HY-148687

SPC5001		Antisense Oligonucleotides
SPC5001 is a locked nucleic acid (LNA)-modifed antisense oligonucleotide (ASO) complementary to human PCSK9 (proprotein convertase subtilisin/kexin type 9) mRNA. SPC5001 can be used for the research of hypercholesterolemia. SPC5001 sequence: 5′-TGmCTACAAAACmCmCA-3′ .

HY-148687A

SPC5001 sodium		Antisense Oligonucleotides
SPC5001 sodium is a locked nucleic acid (LNA)-modifed antisense oligonucleotide (ASO) complementary to human PCSK9 (proprotein convertase subtilisin/kexin type 9) mRNA. SPC5001 sodium can be used for the research of hypercholesterolemia. SPC5001 sequence: 5′-TGmCTACAAAACmCmCA-3′ .

HY-143221

AS-Inclisiran sodium		siRNAs
AS-Inclisiran sodium is the antisense of Inclisiran. Inclisiran (ALN-PCSsc) is a double-stranded small interfering RNA (siRNA) molecule that inhibits the transcription of *PCSK-9*. Inclisiran can be used for hyperlipidemia and cardiovascular disease (CVD) research .

HY-150223

GalNAc unconjugated/naked Inclisiran 1 Publications Verification		siRNAs
GalNAc unconjugated/naked Inclisiran is a double-stranded small interfering RNA (siRNA) without GalNAc conjugation. GalNAc unconjugated/naked Inclisiran inhibits the transcription of *PCSK-9*, and can be used for hyperlipidemia and cardiovascular disease (CVD) research .

HY-132591A

Inclisiran sodium 2 Publications Verification ALN-PCSsc sodium		siRNAs
Inclisiran sodium is a double-stranded small interfering RNA (siRNA) molecule that inhibits the transcription of *PCSK9*. Inclisiran sodium can be used for hyperlipidemia and cardiovascular disease (CVD) research .

HY-132591

Inclisiran ALN-PCSsc		siRNAs
Inclisiran (ALN-PCSsc) is a double-stranded small interfering RNA (siRNA) molecule that inhibits the transcription of *PCSK9*. Inclisiran can be used for hyperlipidemia and cardiovascular disease (CVD) research .

HY-158825

Cepadacursen sodium CIVI007 sodium		Antisense Oligonucleotides
Cepadacursen sodium is a liver-targeting antisense oligonucleotide (ASO), inhibits proprotein convertase subtilisin/kexin type 9 (PCSK9) protein synthesis. Cepadacursen sodium can be used for hypercholesterolemia treatment and the prevention of atherosclerotic cardiovascular disease (ASCVD).

Inquiry Online

Your information is safe with us. * Required Fields.

MCE Japan Authorized Agent ナミキ商事株式会社コスモ・バイオ株式会社
Salutation			Country or Region *
Applicant Name *			Organization Name *
Department *
Email Address *			Product Name *
Cat. No.			Requested quantity *
Phone Number *
Remarks